Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
UTRECHT, The Netherlands, Aug. 31, 2016 -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences:
- Ton Logtenberg, CEO, will present at the 2016 Credit Suisse Antibody Day on Wednesday, September 7 at 2:40 PM ET at Credit Suisse's offices at One Madison Avenue in New York City.
- Management will participate in investor meetings at Citi’s 11th Annual Biotech Conference on Thursday, September 8 at the Mandarin Oriental in Boston.
A live webcast of the Credit Suisse presentation will be available on the Investor page of the Company's website. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Contacts: Merus N.V. Shelley Margetson – [email protected] +31 (0)30 253 8800 Argot Partners Kimberly Minarovich – [email protected] 1-212-600-1902
